CD274 and neoplasm: Adjuvant nivolumab has been approved by FDA for patients with muscle-invasive urothelial carcinoma at high risk of relapse without PD-L1 restrictions whereas EMA so far limits the use to patients with tumor cell PD-L1 expression of ≥1%.